Skip to main content
    R

    Rigel Pharmaceuticals Inc (RIGL)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $47.25
    +0.43 (+0.92%)

    Market Cap: $874.59M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    74%(29/39)
    Avg Surprise
    +73.97%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$0.96
    Range$0.77 - $1.07
    4 analysts
    EPS Revisions
    1
    0
    7d
    0
    4
    30d
    EPS Estimate DriftChange to current
    90d ago$1.27-24.4%
    60d ago$1.22-21.3%
    30d ago$0.89+8.7%
    7d ago$0.960.0%
    Current$0.96
    Revenue Consensus
    $80M
    Range$75M - $83M
    5 analysts
    Period ending Dec 31, 2026
    EPS Consensus$1.78
    Range$0.79 - $2.85
    4 analysts
    Revenue Consensus
    $108M
    Range$96M - $121M
    5 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$1.78---
    Sep 26EST
    		-$0.96---
    Jun 26
    Reported Aug 4
    		$0.88$0.91-3.30%Miss-73.2%
    Mar 26
    Reported May 5
    		$0.44$0.87-49.43%Miss-30.2%
    Dec 25
    Reported Mar 3
    		$1.12$1.20-6.80%Miss+40.0%
    Sep 25
    Reported Nov 4
    		$1.46$0.94+55.32%Beat+108.6%
    Jun 25
    Reported Aug 5
    		$3.28$1.41+132.62%Beat+5566.7%
    Mar 25
    Reported May 6
    		$0.63$0.09+600.00%Beat+226.0%
    Dec 24
    Reported Mar 4
    		$0.80$0.58+38.19%Beat+18947.6%
    Sep 24
    Reported Nov 7
    		$0.70$0.06+1066.67%Beat+333.3%
    Jun 24
    Reported Aug 6
    		$-0.06N/A+66.67%Beat+85.0%
    Mar 24
    Reported May 7
    		$-0.50$-0.27-85.19%Miss+37.5%
    Dec 23
    Reported Mar 5
    		$0.00N/A+114.00%Beat-58.0%
    Sep 23
    Reported Nov 7
    		$-0.30N/A+54.55%Beat+72.7%
    Jun 23
    Reported Aug 1
    		$-0.40$-0.80+50.00%Beat+50.0%
    Mar 23
    Reported May 2
    		$-0.80$-0.93+13.98%Beat+50.0%
    Dec 22
    Reported Mar 7
    		$0.01N/A+109.09%Beat+107.7%
    Sep 22
    Reported Nov 3
    		$-1.10$-1.36+19.12%Beat+8.3%
    Jun 22
    Reported Aug 2
    		$-0.80$-1.21+33.88%Beat+0.0%
    Mar 22
    Reported May 3
    		$-1.60$-1.36-17.65%Miss-172.7%
    Dec 21
    Reported Mar 1
    		$-0.13$-0.13+0.00%Beat-18.2%
    Sep 21
    Reported Nov 2
    		$-1.20$-1.00-20.00%Miss-50.0%
    Jun 21
    Reported Aug 3
    		$-0.80$-1.15+30.43%Beat+20.0%
    Mar 21
    Reported May 5
    		$2.20$0.30+633.33%Beat+1592.3%
    Dec 20
    Reported Mar 2
    		$-0.11$-0.11+0.00%Beat+89.0%
    Sep 20
    Reported Nov 5
    		$-0.80$-1.22+34.43%Beat-14.3%
    Jun 20
    Reported Aug 4
    		$-1.00$-1.33+24.81%Beat+16.7%
    Mar 20
    Reported May 5
    		$0.13$0.13+0.00%Beat+111.8%
    Dec 19
    Reported Feb 27
    		$-1.00$-0.85-17.65%Miss-3433.3%
    Sep 19
    Reported Nov 5
    		$-0.70$-1.07+34.58%Beat+50.0%
    Jun 19
    Reported Aug 6
    		$-1.20$-1.37+12.41%Beat+25.0%
    Mar 19
    Reported May 7
    		$-1.10$-1.28+14.06%Beat+35.3%
    Dec 18
    Reported Feb 28
    		$0.03$0.03+0.00%Beat+116.7%
    Sep 18
    Reported Nov 6
    		$-1.40$-1.50+6.67%Beat+0.0%
    Jun 18
    Reported Aug 8
    		$-1.60$-1.62+1.23%Beat+0.0%
    Mar 18
    Reported May 1
    		$-1.70$-1.70+0.00%Beat-20.6%
    Dec 17
    Reported Mar 6
    		$-0.18$-0.13-38.46%Miss-12.5%
    Sep 17
    Reported Nov 7
    		$-1.40$-1.53+8.50%Beat-
    Jun 17
    Reported Aug 1
    		$-1.60$-1.50-6.67%Miss-
    Mar 17
    Reported May 2
    		$-1.41$-1.08-30.56%Miss-
    Dec 16
    Reported Mar 7
    		$-0.16$-0.17+5.88%Beat-

    Key Metrics

    Valuation
    P/E Ratio12.12EV/EBITDA9.62x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin116.30%Operating Margin29.90%
    ROE126.90%ROIC18.73%
    Financial Health
    Debt/Equity0.09xInterest Coverage15.00x
    Current Ratio1.94xQuick Ratio1.79x
    Trading Statistics
    Beta1.19Avg Volume237.41K
    52-Week High$52.2452-Week Low$24.95

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$47.69
    SMA 20$47.85
    SMA 50$46.21
    SMA 200$36.75
    EMA 10$47.65
    EMA 20$47.50
    EMA 50$45.65
    EMA 200$38.49

    MACD

    Line: 0.41Signal: 0.64Hist: -0.23

    ADX

    ADX: 15.8+DI: 20.9-DI: 20.9

    Aroon & PSAR

    Aroon Up84.0
    Aroon Down16.0
    PSAR$45.63

    Bollinger Bands

    Upper Band$49.69
    Lower Band$46.01
    %B Position768%(Upper)
    Band Width0.34

    RSI (14-Day)

    Neutral
    50.3

    Momentum Oscillators

    Stoch %K35.1
    Stoch %D46.5
    Williams %R-61.5
    ROC (10d)0.6%
    Momentum0.28
    CCI (20d)-26.3
    MFI (14d)55.6

    Volatility Measures

    ATR (14d)$1.81(3.8%)
    StdDev (20d)0.92
    Hist Vol32.9%(Moderate)

    Volume Flow

    VWAP$47.59
    OBV1.5M
    AD Line1.6M
    CMF (20d)0.068

    Volume Metrics

    Avg Vol (20d)241.5K
    Vol Ratio0.7x
    VWMA (20d)$47.70

    Pivot Points

    R3$49.37
    R2$48.68
    R1$47.75
    Pivot Point$47.06
    S1$46.13
    S2$45.44
    S3$44.51

    Advanced Oscillators

    TSI7.12
    Ultimate Osc46.5
    KST33.65

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$78.70M$58.82M$69.80M$69.46M$101.69M$53.33M$57.60M$55.31M$36.84M$29.53M$35.79M$28.13M
    Cost of Revenue$8.53M$4.61M$5.96M$4.75M$4.50M$4.41M$5.79M$8.03M$2.81M$2.02M$3.79M$1.27M
    Gross Profit$70.18M$54.21M$63.85M$64.71M$97.18M$48.92M$51.81M$47.28M$34.03M$27.51M$32.00M$26.87M
    Operating Expenses$46.60M$42.33M$40.68M$36.29M$36.08M$36.15M$35.15M$33.23M$33.59M$34.48M$30.04M$31.33M
    R&D$13.96M$11.68M$10.69M$7.35M$6.82M$8.44M$5.63M$6.18M$5.54M$6.03M$3.19M$6.47M
    SG&A$32.64M$30.65M$29.99M$28.94M$29.26M$27.71M$29.52M$27.04M$28.05M$28.45M$26.85M$24.86M
    Operating Income$23.57M$11.88M$23.17M$28.42M$61.10M$12.77M$16.66M$14.06M$447,000$-6,966,000$1.97M$-4,465,000
    Interest Income$789,000$1.21M$1.24M$1.09M$753,000$591,000$522,000$425,000$552,000$593,000$678,000$672,000
    Interest Expense$779,000$1.43M$1.70M$1.89M$1.87M$1.85M$1.96M$2.06M$2.03M$1.87M$1.91M$1.90M
    Income Before Tax$23.59M$11.66M$22.71M$27.62M$59.98M$11.51M$15.22M$12.42M$-1,030,000$-8,247,000$737,000$-5,692,000
    Income Tax Expense$6.29M$3.00M$-245,351,000$-280,000$369,000$65,000$881,000$0$0$0$0$0
    Net Income$17.29M$8.65M$268.06M$27.90M$59.61M$11.45M$14.34M$12.42M$-1,030,000$-8,247,000$737,000$-5,692,000
    EBITDA$24.39M$12.31M$23.53M$28.56M$61.46M$13.19M$16.98M$14.60M$901,000$-6,771,000$2.00M$-4,278,000
    EBIT$23.57M$11.88M$23.17M$28.42M$61.10M$12.77M$16.66M$14.06M$447,000$-6,966,000$1.97M$-4,465,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about RIGL

    News

    Rigel Pharmaceuticals, Inc. (RIGL) stock price, news, quote and history

    This Yahoo Finance page provides a detailed overview of Rigel Pharmaceuticals, Inc. (RIGL), including its current stock price, recent performance, key financial metrics, and historical data. As of close on October 13...

    Yahoo Finance Australia•10/13/26•Bearish

    H.C. Wainwright Sticks to Their Buy Rating for Rigel (RIGL)

    H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating for Rigel (RIGL) with a price target of $85.00. Pantginis is a 5-star analyst with a 25.8% average return. Rigel reported quarterly revenue of $78.7...

    The Globe and Mail•10/7/26•Bullish

    Trading Systems Reacting to (RIGL) Volatility

    Rigel Pharmaceuticals Inc. (NASDAQ: RIGL) is experiencing volatility, with weak near-term sentiment potentially preceding shifts in mid and long-term outlook. AI models have generated three trading strategies—Position...

    Stock Traders Daily•10/6/26•Somewhat-Bearish

    Rigel Pharmaceuticals Inc. Advanced Charts | RI2

    This article provides advanced chart information and financial data for Rigel Pharmaceuticals Inc. (RI2) on the Frankfurt market. It includes details such as the current price, analyst ratings...

    Barron's•10/5/26•Somewhat-Bearish

    Rigel Pharmaceuticals Inc. Research & Ratings | RI2

    This Barron's article provides research and ratings for Rigel Pharmaceuticals Inc. (RI2), a clinical-stage biotechnology company. It includes analyst ratings with an average price target, key financial metrics...

    Barron's•10/5/26•Somewhat-Bearish

    RIGL Valuation and Fair Value

    P/E
    12.1x
    Forward P/E
    9.3x
    EV/EBITDA
    9.6x
    PEG
    -0.1x
    P/B
    2.1x
    See GNG's fair value

    RIGL Profitability: Margins, ROIC and FCF

    Gross margin
    91.4%
    Operating margin
    29.9%
    Net margin
    116.3%
    ROIC
    18.7%
    ROE
    126.9%
    FCF margin
    28.7%

    RIGL Competitors

    CompanyTicker
    MoonLake ImmunotherapeuticsMLTX
    Kura Oncology IncKURA
    Theravance Biopharma IncTBPH
    Si-Bone IncSIBN
    Beta Bionics, Inc. Common StockBBNX
    Jade Biosciences, Inc.JBIO
    Quidel CorporationQDEL
    Alto Neuroscience, Inc.ANRO

    Sector: Healthcare

    RIGL Analyst Ratings

    Consensus
    Buy
    Analysts
    5
    Strong Buy
    0
    Buy
    3
    Hold
    2
    Sell
    0
    Strong Sell
    0

    RIGL Bull Case vs Bear Case

    Bull case

    • RIGL earns an 18.7% return on invested capital.
    • RIGL converts 28.7% of revenue into free cash flow.
    • RIGL has a 116.3% net profit margin.

    Bear case

    • RIGL's quarterly revenue changed -22.6% year over year.

    RIGL Earnings: Beat Rate and Next Report

    Beat rate
    5 of 8 quarters (62.5%)
    Average surprise
    229.2%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $0.96
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    0 up, 4 down

    Frequently Asked Questions About RIGL

    Does RIGL pay dividends?

    Rigel Pharmaceuticals Inc (RIGL) does not currently pay a regular dividend.

    What is RIGL's P/E ratio?

    Rigel Pharmaceuticals Inc has a price-to-earnings (P/E) ratio of 12.12.

    What is RIGL's market cap?

    Rigel Pharmaceuticals Inc (RIGL) has a market capitalization of $874.59M with a current stock price of $47.25.

    Related stocks

    Sector: Healthcare

    All stocks starting with R

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In